Digitisation | August 10, 2021
Fulgent Genetics and Helio Health partners to commercialize early cancer detection tests
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
_logo_256_384.jpg){kind=logo}
It supports sequencing-based COVID 19 surveillance in India
Robust demand for the product across the Middle East, Africa and Latin America
Price band in the range of Rs 933 to Rs 954
As of 2025, the new Translational Science Center will offer room for more than 500 scientists, who will conduct research in a wide variety of fields ranging from the identification of disease biomarkers to the development of targeted therapies
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli in India
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
Subscribe To Our Newsletter & Stay Updated
